This technology was explored in the context of an AML model developing CAR-NK engineered with a logic CAR to target CD33 and/or FLT3 on the membrane of leukemic cells and with a not-logic gate, with inhibitory CAR enabling CAR-NK to target endomucin, a protective antigen unique to normal HSCs [50]. The gene discussed is FLT3; the disease is acute myeloid leukemia.